Meta AnalysisID 6537
辛夷鼻炎丸治疗过敏性鼻炎的有效性和安全性：系统评价和Meta分析
CRD42020201625
1. Is the Xinyi Biyan Pill an effective treatment for patiens with allergic rhinitis? 2. How does the efficacy of Xinyi Biyan Pill compare to that with receving acupuncture, having western medicines, blank control, place
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6537
- Evidence Id
- 15095
- Core Evidence Id
- 15095
- Source Meta Analysis Id
- 6519
- Herb2 Meta Analysis Id
- HBMA006519
- Crd Id
- CRD42020201625
- Title
- Efficacy and Safety of Xinyi Biyan Pill for Allergic Rhinitis: A Systematic Review and Meta-analysis
- Review Question
- 1. Is the Xinyi Biyan Pill an effective treatment for patiens with allergic rhinitis? 2. How does the efficacy of Xinyi Biyan Pill compare to that with receving acupuncture, having western medicines, blank control, placebo control and other interventions? 3. What moderating variables are associated with treatment effectiveness in studies of Xinyi Biyan Pill for patients with allergic rhinitis?
- Study Type Included
- All RCTs which published in English/Chinese region will be included without any regional restrictions. Non-RCT, quasi-RCTs, cluster RCTs, animal studies, literature reviews, case reports, retrospective studies, and studies which no data are available will not be involved.
- Condition Being Studied
- Allergic rhinitis (AR) is a common symptomatic, inflammatory and immunological disorder of nasal mucosa results from allergen exposure triggered IgE response. Epidemiology of allergic rhinitis varies according to different factors like genetic constitution, racial differences, socio-economic conditions, chances of exposure to different allergens, sex, growth stages. AR shows high prevalence among developed countries. AR is managed with first and second anti histamines(56%), intra nasal corticosteroids (25%) and mast cell stabilizers (19%). Prolonged usage of these medications are necessary in beating the disease as far as the recurrence is concerned. This may lead to numerous serious health hazards. Studies have shown that negative effects of sedative anti-histamines last to the succeeding day disturbing the day time performance.
- Participant
- Participants with all types of allergic rhinitis (including intermittent allergic rhinitis and persistent allergic rhinitis) regardless of gender, age, etiology, ethnic group, severity, diagnosed with specific criteria (i.e. mention any one of criteria for diagnosis of allergic rhinitis) are eligible for inclusion. Complicated with asthma, nasosinusitis are excluded.
- Animal
- Human Disease Modelled
- Intervention
- Treatment of the Xinyi Biyan Pill, including dosage forms of pieces of traditional Chinese medicine, boil-free granule of Traditional Chinese medicine, Chinese patent drug and other available forms.
- Comparator Control
- Xinyi Biyan Pill was main intervention measure in the experimental group. The control group could be other interventions such as acupuncture, western medicines, blank control, placebo control and other interventions, except for the main intervention measures.
- Main Outcome
- 1. Total Nasal Symptom Score (TNSS) and four key symptoms' scores; 2. Rhinitis Quality of Life Questionnaire (RQLQ); 3. VAS score （Guidelines for the diagnosis and treatment of allergic rhinitis，Mount Wuyi，2009； ARIA，2010); 4.Total effective rate; 5.Score for signs and symptoms (Diagnostic and therapeutic criteria for allergic rhinitis，Haikou，revised in 1997; Principles of diagnosis and treatment and recommended program of allergic rhinitis， Lanzhou, 2004; Criteria for the diagnosis and treatment combined Chinese and western medicine of allergic rhinitis (draft)); 6.The improvemwnt of disease classification （Diagnostic and therapeutic criteria for allergic rhinitis, 1990). Measures of effect 1. Total Nasal Symptom Score (TNSS) and four key symptoms' scores; 2. Rhinitis Quality of Life Questionnaire (RQLQ); 3. VAS score （Guidelines for the diagnosis and treatment of allergic rhinitis，Mount Wuyi，2009； ARIA，2010); 4.Total effective rate; 5.Score for signs and symptoms (Diagnostic and therapeutic criteria for allergic rhinitis，Haikou，revised in 1997; Principles of diagnosis and treatment and recommended program of allergic rhinitis， Lanzhou, 2004; Criteria for the diagnosis and treatment combined Chinese and western medicine of allergic rhinitis (draft)); 6.The improvemwnt of disease classification （Diagnostic and therapeutic criteria for allergic rhinitis, 1990).
- Outcome Measure
- Additional Outcome
- 1. TNNSS; 2. Laboratory index, eg. IgE, IL; 3.Recurrence rate; 4.Time when the symptoms disappear; 5.Frequency of seizure; 6.The case of drug reduction. Measures of effect 1. TNNSS; 2. Laboratory index, eg. IgE, IL; 3.Recurrence rate; 4.Time when the symptoms disappear; 5.Frequency of seizure; 6.The case of drug reduction.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Humans; Rhinitis, Allergic
- Contact
- Qinxiu Zhang [email protected]
- Organisational Affiliation
- 1.Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. 2.School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China. 1.http://sctcm120.cdutcm.edu.cn/
- Funding Source
- the World Federation of Chinese Medicine Societies- International Guidelines for the Diagnosis and Treatment of Allergic Rhinitis in Traditional Chinese Medicine Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span> SCM NP 2020-0097
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Chinese-Simplified, English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-07-29
- Registration Date
- 2020-08-29
- Anticipated Start Date
- 2020-07-30
- Anticipated Completion Date
- 2020-10-28
- Title Cn
- 辛夷鼻炎丸治疗过敏性鼻炎的有效性和安全性：系统评价和Meta分析
- Title En
- Efficacy and Safety of Xinyi Biyan Pill for Allergic Rhinitis: A Systematic Review and Meta-analysis
- Bilingual Status
- complete